中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
14期
908-912
,共5页
魏熙胤%王晶%臧凤琳%张飞%刘竹君%张翠翠%李凯
魏熙胤%王晶%臧鳳琳%張飛%劉竹君%張翠翠%李凱
위희윤%왕정%장봉림%장비%류죽군%장취취%리개
血管内皮细胞%流式细胞术%非小细胞肺癌%外周血
血管內皮細胞%流式細胞術%非小細胞肺癌%外週血
혈관내피세포%류식세포술%비소세포폐암%외주혈
circulating endothelial cells%flow cytometry%non-small cell lung cancer%peripheral blood
目的：检测非小细胞肺癌（NSCLC）患者外周血中活化血管内皮细胞（aCECs）数量，分析其与抗血管生成疗效的关系，以期寻找能够早期反映抗血管生成疗效的标志物。方法：将142例NSCLC患者分为化疗组和联合组（化疗+恩度），应用流式细胞术检测患者各个治疗周期外周血中CD105和CD146的表达状态，观察以其标记的aCECs变化趋势并分析其与疗效的相关性。结果：联合组在第8天、第29天、第2个周期后、第50天、第71天、第4个周期后aCEC均较基线明显升高（P<0.05），其中疾病进展（progression disease，PD）患者于治疗后aCECs升高更为显著，治疗后较基线升高均有统计学意义（P<0.05）。治疗周期与治疗前后aCECs差值呈负相关（r=-0.970，P=0.001），治疗后aCECs的变化差值与TTP间呈负相关（r=-0.351，P=0.039）。结论：CD105和CD146能够反映内皮细胞的活化状态，对药物治疗反应敏感，可作为aCECs的理想标志物；肿瘤进展时aCECs呈上升趋势，抗血管生成有效治疗使其波动下降；检测aCECs数目，可以帮助预判抗血管生成治疗疗效。
目的：檢測非小細胞肺癌（NSCLC）患者外週血中活化血管內皮細胞（aCECs）數量，分析其與抗血管生成療效的關繫，以期尋找能夠早期反映抗血管生成療效的標誌物。方法：將142例NSCLC患者分為化療組和聯閤組（化療+恩度），應用流式細胞術檢測患者各箇治療週期外週血中CD105和CD146的錶達狀態，觀察以其標記的aCECs變化趨勢併分析其與療效的相關性。結果：聯閤組在第8天、第29天、第2箇週期後、第50天、第71天、第4箇週期後aCEC均較基線明顯升高（P<0.05），其中疾病進展（progression disease，PD）患者于治療後aCECs升高更為顯著，治療後較基線升高均有統計學意義（P<0.05）。治療週期與治療前後aCECs差值呈負相關（r=-0.970，P=0.001），治療後aCECs的變化差值與TTP間呈負相關（r=-0.351，P=0.039）。結論：CD105和CD146能夠反映內皮細胞的活化狀態，對藥物治療反應敏感，可作為aCECs的理想標誌物；腫瘤進展時aCECs呈上升趨勢，抗血管生成有效治療使其波動下降；檢測aCECs數目，可以幫助預判抗血管生成治療療效。
목적：검측비소세포폐암（NSCLC）환자외주혈중활화혈관내피세포（aCECs）수량，분석기여항혈관생성료효적관계，이기심조능구조기반영항혈관생성료효적표지물。방법：장142례NSCLC환자분위화료조화연합조（화료+은도），응용류식세포술검측환자각개치료주기외주혈중CD105화CD146적표체상태，관찰이기표기적aCECs변화추세병분석기여료효적상관성。결과：연합조재제8천、제29천、제2개주기후、제50천、제71천、제4개주기후aCEC균교기선명현승고（P<0.05），기중질병진전（progression disease，PD）환자우치료후aCECs승고경위현저，치료후교기선승고균유통계학의의（P<0.05）。치료주기여치료전후aCECs차치정부상관（r=-0.970，P=0.001），치료후aCECs적변화차치여TTP간정부상관（r=-0.351，P=0.039）。결론：CD105화CD146능구반영내피세포적활화상태，대약물치료반응민감，가작위aCECs적이상표지물；종류진전시aCECs정상승추세，항혈관생성유효치료사기파동하강；검측aCECs수목，가이방조예판항혈관생성치료료효。
Objective: This study aimed to examine the number of activated circulating endothelial cells (aCECs) in the peripheral blood of patients with non-small cell lung cancer (NSCLC), and investigate the relationship among aCECs, anti-angiogenic therapy, and prognosis of NSCLC patients. This study also aimed to identify novel predictive markers for anti-angiogenic therapy, and provide basic data and experimental basis for establishing an evaluation system for this therapy. Methods: A total of 142 NSCLC patients were randomly divided into the chemotherapy group (Group 1) and combined therapy group (i.e., chemotherapy plus endostatin, Group 2). The number of aCECs was measured using flow cytometry by detecting the expression status of CD105 and CD146 in the peripheral blood. The correlation between the changes in aCECs and efficacy of drug treatment was statistically analyzed using SPSS software. Results:The number of aCECs in Group 2 increased significantly at 8 and 29 d, two cycles, 50 and 71 d, and four cycles after treatment, respectively (P<0.05). In particular, aCECs amount in cases of progressive disease increased more significantly after combined therapy (P<0.05). A negative correlation was found between the treatment cycle and difference in aCECs amount before and after therapy (r=-0.970, P=0.001). A negative correlation was also observed between the difference in aCECs amount and time to tumor progression (TTP) (r=-0.351, P=0.039). Therefore, the difference in aCECs amount before and after therapy could serve as an important predictor for TTP in NSCLC patients. Conclusion:CD105 and CD146 reflected the activation status of endothelial cells, and responded to the drug treatment. Thus, CD105 and CD146 could act as ideal markers for aCECs. The number of aCECs increased during cancer progression, but significantly decreased after long-term treatment. Therefore, the change in aCECs amount may be a useful marker in predicting the efficacy of anti-angiogenic therapy.
